Use of Intraarticular Hyaluronic Acid in the Management of Knee Osteoarthritis in Clinical Practice by Cooper, C et al.
Arthritis Care & Research
Vol. 69, No. 9, September 2017, pp 1287–1296
DOI 10.1002/acr.23204
VC 2017, American College of Rheumatology
REVIEW ARTICLE
Use of Intraarticular Hyaluronic Acid in the
Management of Knee Osteoarthritis in
Clinical Practice
CYRUS COOPER,1 FRANC¸OIS RANNOU,2 PASCAL RICHETTE,3 OLIVIER BRUYERE,4
NASSER AL-DAGHRI,5 ROY D. ALTMAN,6 MARIA LUISA BRANDI,7 SABINE COLLAUD BASSET,8
GABRIEL HERRERO-BEAUMONT,9 ALBERTO MIGLIORE,10 KAREL PAVELKA,11
DANIEL UEBELHART,12 AND JEAN-YVES REGINSTER4
Introduction
Knee osteoarthritis (KOA) is a chronic disorder characterized
by joint pain, increasing physical disability, and progressive
cartilage degeneration, which can lead to total knee arthro-
plasty (TKA). Despite extensive research, the complex patho-
physiology of KOA remains incompletely understood. As a
result, no established disease-modifying treatment exists
today, and the management of KOA still relies on a combina-
tion of nonpharmacologic and pharmacologic modalities (1)
primarily intended to relieve the symptoms of pain and loss
of knee function. In clinical practice, acetaminophen and
nonsteroidal antiinflammatory drugs (NSAIDs) are generally
recommended to relieve pain and improve joint function
(2–5). However, due to their vascular and gastrointestinal
toxicity (6,7), the risk-benefit ratio of these rapid-acting drugs
might not be favorable, particularly for long-course therapies
and within the aging population in which KOA is most prev-
alent (8). Intraarticular (IA) injections of corticosteroids such
as triamcinolone hexacetonide and methylprednisolone ace-
tate are also commonly prescribed. As a systemic absorption
occurs following IA corticosteroid injection, systemic
adverse events (AEs) can be expected and precautions
should be observed in patients with concomitant diseases
such as hypertension or diabetes mellitus (9–13).
IA hyaluronic acid (HA) is a local treatment modality
devoid of the systemic AEs observed after IA corticosteroid
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injection or oral administration of analgesics and NSAIDs.
Thus, IAHA represents an alternative to analgesics and
NSAIDs in patients with comorbidities, as well as a second-
ary option in case of inadequate response to first-line phar-
macologic KOA treatments (14). Registered as medical
devices in the US, IAHA preparations are currently
approved for the symptomatic treatment of KOA, one of the
most commonly affected joints. Despite being widely
employed in the daily management of KOA for almost 20
years in the US (about 30 years in Europe and Japan), contro-
versies persist regarding their efficacy and safety, as high-
lighted by discrepancies in the guidelines related to the use
of IAHA in clinical practice (2–5,15), which largely reflect
the divergent conclusions drawn by meta-analyses on the
topic (16–30).
For this purpose, the European Society for Clinical and
Economic Aspects of Osteoporosis and Osteoarthritis
(ESCEO) convened an international task force of experts in
OA and clinical research methodology. Seven members of
this working group (CC, FR, PR, OB, GH-B, AM, and DU)
were entrusted with the task of preparing a review on diverse
aspects of the use of IAHA in the management of KOA. Cur-
rent knowledge on the mode of action, efficacy, effective-
ness, safety, and cost-effectiveness of this treatment
modality was presented and discussed at a 1-day meeting in
January 2016 in Geneva (Switzerland).
The objective of this review is to provide specialists and
practicing physicians with clear, concise, and reasoned
answers to questions they might have on the use of IAHA in
the management of KOA.
Efficacy
Efficacy of IAHA on pain and joint function has been evalu-
ated in numerous randomized controlled trials (RCTs). Con-
sequently, 15 meta-analyses/systematic reviews assessing
the symptomatic effects of IAHA on KOA have been pub-
lished to date (16–30). Six of them concluded on a clear effi-
cacy of IAHA (17,20,24,27,29,30), 4 considered it as a
marginally efficacious treatment modality (16,19,25,26), and
2 meta-analyses found no significant difference in efficacy
between IAHA and IA placebo (18,21) (Table 1).
The reported effect sizes (ES) for pain favored IAHA over
IA placebo and ranged from 0.20 (30) to 0.46 (24). Heteroge-
neity of outcomes between trials was relatively high in sev-
eral meta-analyses (16,20,24,27). As shown by Bannuru et al,
the benefits of IAHA vary over time, with a maximal effect
on pain at 8 weeks (ES 0.46 [95% confidence interval (95%
CI) 0.28, 0.65]) that is still observable at 24 weeks (ES 0.21
[95% CI 0.10, 0.31]) (24). This time dependency may partly
contribute to the differences in pain estimates that have been
observed between meta-analyses. Another possible explana-
tion is the inclusion of clinical trials that widely differ in
methodological quality. Thus, when the analysis was
restricted to high-quality trials, an ES of 0.34 (95% CI 0.02,
0.67) and of 0.20 (95% CI 0.03, 0.37) in favor of IAHA was
obtained at 8 and 24 weeks, respectively (24). These results
were confirmed by Richette et al, who examined clinical
data obtained from IA placebo controlled trials with a low
risk of bias only (n5 8) in order to reach the highest level of
evidence. Based on an ES of 0.20 (95% CI 0.12, 0.29) for pain
at 12 weeks, the authors concluded that IAHA provided a
moderate but real effect on pain in patients with KOA (30).
Since the estimates for pain mentioned above were based
on the difference between the IA placebo and the IAHA
effects, it is worth noting that evidence for a clinically signifi-
cant response of the IA delivery method itself has recently
been demonstrated in a meta-analysis, with an ES of 0.29
(95% credible interval [95% CrI] 0.04, 0.54) in favor of IA
placebo compared with oral placebo (29). In the same study,
different treatment options of KOA were compared based on
their ES versus oral placebo at 3 months. IAHA was found to
be the most efficacious intervention with an ES of 0.63 (95%
CrI 0.39, 0.88), followed by IA corticosteroids (ES 0.61 [95%
CrI 0.32, 0.89]), diclofenac (ES 0.52 [95% CrI 0.34, 0.69]),
ibuprofen (ES 0.44 [95% CrI 0.25, 0.63]), naproxen (ES 0.38
[95% CrI 0.27, 0.49]), celecoxib (ES 0.33 [95% CrI 0.25,
0.42]), and IA placebo. With an ES of 0.18 (95% CrI 0.04,
0.33), acetaminophen was considered as not superior to oral
placebo in relieving pain (29). In direct comparison, IAHA
was shown to be not significantly different from continuous
oral NSAID treatment at 4 and 12 weeks regarding pain,
function, and stiffness (28), and superior to IA corti-
costeroids from 8 to 26 weeks regarding pain (23).
Effectiveness
The extent to which IAHA achieves its intended effect in the
“real-life” clinical setting cannot be measured in RCTs, since
patients in such studies are not representative of those seen
in usual practice. Therefore, observational studies of real
practice are better suited in evaluating effectiveness of IAHA.
Petrella and Wakeford retrospectively assessed the effec-
tiveness of IA crosslinked HA (hylan) using the Southwest-
ern Ontario database, a Canadian real-world cohort (31). For
this purpose, they identified 1,263 patients with OA in 1 or
both knees that received 2 consecutive series of IA hylan
injections and no other prescribed OA medications. They
compared them to a cohort of 3,318 demographically
matched KOA patients who were never treated with IAHA.
All patients were evaluated fully between 2006 and 2012.
Results showed that in the group of patients who received
repeated treatments of IA hylan, pain at rest and pain after a
6-minute walk decreased by mean6SD 3.761.8 points and
5.66 1.7 points on a 10-point visual analog scale, respec-
tively. In parallel, the distance walked in a 6-minute walk
test increased on average by 115 meters in this patient group.
These improvements in pain and physical function were
Significance & Innovations
 Besides efficacy and safety, this review also
addresses less frequently evaluated aspects of
the intraarticular use of hyaluronic acid (HA) in
the management of knee osteoarthritis (KOA)
such as effectiveness and efficiency.
 This is the first time that a group of experts
recommends systematic repeated intraarticular
HA treatment in KOA patients who had a benefi-
cial response to a previous cycle of treatment.
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Table 1. Meta-analyses evaluating intraarticular hyaluronic acid in the symptomatic treatment of knee osteoarthritis*
Reference Comparator Main outcome ES (95% CI) General outcome
Lo et al, 2003 (16) IA placebo Pain change from BL at M1–4 SMD5 0.32 (0.17, 0.47) Intermediate
Wang et al,
2004 (17)
IA placebo Pain on movement MPD5 7.9 (4.1, 11.7) Positive
Arrich et al,
2005 (18)
IA placebo Pain on movement at W2–6 WMD5 3.8 (21.4, 9.1)
I2581%
Negative (no clinical
difference)
Pain on movement at W10–14 WMD5 4.3 (0.9, 7.6)
I250%
Pain on movement at W22–30 WMD5 7.1 (2.4, 11.8)
I250%
Modawal et al,
2005 (19)
IA placebo Pain change at W5–7 MD517.6 (7.5, 28.0) Intermediate
Pain change at W8–12 MD518.1 (6.3, 29.9)
Pain change at W15–22 MD54.4 (215.3, 24.1)
Bellamy et al,
2006 (20)
IA placebo Pain/function at W5–13 WMD/SMD variable for
different HA products
Positive
Medina et al,
2006 (21)
IA placebo Pain MPD5 2.4 (20.6, 5.5) Negative (no statistical
difference)Function MPD5 2.0 (20.8, 4.9)
Stiffness MPD5 5.5 (2.2, 8.8)
Reichenbach et al,
2007 (22)
IA hylan Pain at end of followup SMD520.27 (20.55, 0.01)
I2588%
HA.hylan
Bannuru et al,
2009 (23)
IA CS Pain change from BL at W2 SMDg520.39 (20.65, 20.12)
I2547%
Positive (HA.CS
from W8 onward)
Pain change from BL at W4 SMDg520.01 (20.23, 0.21)
I2537%
Pain change from BL at W8 SMDg5 0.22 (20.05, 0.49)
I2547%
Pain change from BL at W12 SMDg5 0.35 (0.03, 0.66)
I2549%
Pain change from BL at W26 SMDg5 0.39 (0.18, 0.59)
I250%
Bannuru et al,
2011 (24)
IA placebo Pain change from BL at W4 SMDg5 0.31 (0.17, 0.45)
I2575%
Positive
Pain change from BL at W8 SMDg5 0.46 (0.28, 0.65)
I2575%
Pain change from BL at W12 SMDg5 0.25 (0.15, 0.36)
I2560%
Pain change from BL at W16 SMDg5 0.20 (0.11, 0.30)
I257%
Pain change from BL at W24 SMDg5 0.21 (0.10, 0.31)
I2532%
Colen et al, 2012 (25) IA placebo Pain change from BL at M3 vs. IA placebo:
WMD5 10.2 (4.4, 16.0)
I2592%
Intermediate
vs hylan
SMD5 0.07 (20.10, 0.24)
I2572%
Rutjes et al, 2012 (26) Sham or no
intervention
Pain at end of followup SMD: 0.37 (0.28, 0.46)
t250.09
Intermediate
Miller and Block,
2013 (27)
IA placebo Pain at W4–13 SMD5 0.43 (0.26, 0.60)
I2573%
Positive
Pain at W14–26 SMD5 0.38 (0.21, 0.55)
I2575%
Function at W4–13 SMD5 0.34 (0.16, 0.51)
I2554%
Function at W14–26 SMD5 0.32 (0.18, 0.45)
I2569%
Bannuru et al,
2014 (28)
NSAIDs Pain change from BL at W4 SMDg520.01 (20.18, 0.15)
I250%
Positive
(HA5NSAIDs)
Pain change from BL at W12 SMDg5 0.05 (20.17, 0.28)
I2530%
Pain change from BL at
end of followup
SMDg5 0.07 (20.10, 0.24)
I2516%
(continued)
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significantly greater than those achieved in KOA-matched
patients treated with other prescribed OA medications
(intergroup comparison P, 0.012 for pain at rest, P, 0.001
for pain after a 6-minute walk, and P, 0.001 for distance
walked in a 6-minute walk test). Previous observational stud-
ies already found that IAHA was effective in relieving pain
and improving knee function for up to 6 months (32–34).
Such pragmatic trials were also adapted in the assessment of
longer-term outcomes.
Three recent retrospective studies examined the time from
diagnosis of KOA to TKA and whether this time would be
influenced by the use of IAHA (35–37). Large populations of
insured subjects were screened and about 250,000 TKAs were
reviewed after exclusions. In these studies, the median time to
arthroplasty from the index time of KOA diagnosis was 114,
86, and 326 days in those not receiving IAHA. The median
time from diagnosis to TKA in those receiving IAHA was 484,
585, and 908 days. Two studies including 65-year-old subjects
showed a 1-year increase in time to surgery (35,36). The study
including only those younger than age 65 years showed an
increase in time to surgery of 1.6 years (37). All studies showed
increased time to surgery with increased series of IAHA, and 2
studies suggested additional benefit from higher molecular
weight (MW) HA products (36,37). The consistency of results
from the 3 studies suggests both clinical and economic benefits
to IAHA. However, they are insufficient to prove that the
observed delay in time to TKA results from the use of IAHA, as
treatment was not allocated randomly. Thus, between-group
differences might reflect a bias in patient selection.
As the evidence for efficacy of IAHA on knee pain and
function is currently established, the ESCEO task force sug-
gests promoting pragmatic trials in order to focus clinical
research on the effectiveness of IAHA in real-life conditions,
considering the patient situation in terms of individual and
disease characteristics, medical history, and comorbidities.
Safety
Seven meta-analyses of RCTs comparing IAHA to IA placebo
evaluated the safety of the intervention (17,18,20,21,26,27,29).
AEs occurred slightly more often among patients who
received an IAHA treatment (relative risk [RR] 1.08 [95% CI
1.01, 1.15]) (18). However, they were usually mild transient
local reactions such as pain at the injection site and swelling,
with an RR of 1.19 (95% CI 1.01, 1.41) according to Wang
et al (17) or RR 1.34 (95% CI 1.13, 1.60) according to Rutjes
et al (26). The use of IAHA has also been associated with
increased risk of flares (RR 1.51 [95% CI 0.84, 2.72]) and effu-
sion at the injected knee (RR 1.15 [95% CI 0.38, 3.54]), which
were not statistically significant (26). In contrast, the meta-
analysis of US-approved HA products by Miller and Block
reported no statistically significant differences between
IAHA and IA placebo for any safety outcomes, including
serious AEs (P5 0.12), treatment-related serious AEs
(P5 1.0), study withdrawal (P5 1.0), and AE-related study
withdrawal (P5 0.46) (27). Only Rutjes et al raised concerns
about the safety of IAHA. Their meta-analysis emphasized
an increased risk of serious AEs (RR 1.41 [95% CI 1.02,
1.97]) and dropouts due to AEs (RR 1.33 [95% CI 1.01, 1.74]).
However, these findings have been criticized regarding the
methodological rigor with which the serious AEs were ana-
lyzed and the biologic plausibility of the reported events
(38,39).
As shown in a review by Pagnano and Westrich (40), the
safety of IAHA appears to remain unchanged with multiple
courses of treatment, while there might be an increase in AEs
after the first hylan injection(s). Leopold et al reported that
patients receiving multiple cycles of IA hylan exhibited more
than an 8-fold increase in the frequency of acute local reac-
tions compared with patients receiving only 1 course (41).
In addition to the AEs mentioned above, postmarketing
device surveillance highlighted the occurrence of rare cases
of localized inflammatory reactions such as pseudosepsis/
severe acute inflammatory reactions, predominantly reported
after avian high-MW crosslinked HA injections (hylan) (42).
In comparison with other pharmacologic interventions for
the treatment of KOA, IAHA therapy was shown to exhibit
fewer systemic AEs than acetaminophen or oral NSAIDs, but
more local reactions (43). These events were reported to be
Table 1. (Cont’d)
Reference Comparator Main outcome ES (95% CI) General outcome
Bannuru et al,
2015 (29)
Other options Pain change
from BL at M3
vs IA placebo:
SMDg50.34 (0.26, 0.42)†
Positive
vs oral placebo:
SMDg50.63 (0.39, 0.88)†
Function change
from BL at M3
vs IA placebo:
SMDg50.30 (0.20, 0.40)†
vs oral placebo:
SMDg50.45 (0.08, 0.84)†
Richette et al,
2015 (30)
IA placebo Pain at W12 SMD5 0.20 (0.12, 0.29)
I25 32%
Positive
Function at W12 SMD5 0.12 (0.02, 0.22)
I25 0%
* Positive effect sizes (ES) favor intraarticular hyaluronic acid, negative ES favor comparator. 95% CI595% confidence interval; IA5 intraarticular;
BL5 baseline; M5month; SMD5 standardized mean difference; MPD5mean percent difference; W5week; WMD5weighted mean difference;
MD5mean difference; HA5hyaluronic acid; hylan5hylan G-F 20; CS5 corticosteroid; SMDg5 standardized mean difference adjusted for small sam-
ple size (Hedges’ g); NSAIDs5nonsteroidal antiinflammatory drugs.
† 95% credible interval.
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similar between different IA therapies, i.e., HA and corti-
costeroids. Withdrawals due to AEs were more common
among patients receiving acetaminophen or NSAIDs than IA
therapies (29). As a result, after almost 30 years of use, IAHA
is usually recognized as a safe treatment modality for KOA.
Current guidelines
As shown in the previous sections dealing with the efficacy,
effectiveness, and safety of IAHA, there is increasing evi-
dence that the risk-benefit balance is favorable to the use of
IAHA in the management of KOA (24,26,27,29,30,44). How-
ever, while IAHA was initially clearly recommended by
national and international professional societies, such as the
Osteoarthritis Research Society International (OARSI) (45),
the European League Against Rheumatism (EULAR) (2), and
the American College of Rheumatology (ACR) (46), some cli-
nicians, researchers, and decision makers feel that current
guidelines are conflicting and less favorable than 10 years
ago (47,48). Nevertheless, there is relative general agreement
on the place of IAHA in the management of KOA across
organizations (Table 2). Apart from the American Academy
of Orthopedic Surgeons, which refutes the use of IAHA
based on insufficient clinical efficacy compared with IA
saline (15), and the National Institute for Health and Care
Excellence, which does not assess the modality at all (5), the
use of IAHA is recommended as second-line treatment of
KOA (Table 2).
Based on the available evidence and guidelines, the
ESCEO recommends using IAHA in patients remaining
symptomatic despite continuous or intermittent treatment
with conventional pharmacologic treatment modalities, i.e.,
acetaminophen, symptomatic slow-acting drugs, and
NSAIDs, as well as in patients with comorbidities precluding
the use of NSAIDs. This positioning is clearly highlighted in
the ESCEO treatment algorithm for the management of KOA
and may help the prescribing physician prioritize interven-
tions (14,49). The ACR guidelines move in the same direction
and present IAHA as an alternative to unsatisfactory initial
pharmacologic therapy (46). Furthermore, they emphasize its
particular interest for patients ages .75 years, who are not
recommended to take oral NSAIDs (4,14). EULAR considers
the use of IAHA for pain relief and knee functional improve-
ment based on level 1B evidence (2).
OARSI guidelines for the nonsurgical management of
KOA probably raise the most considerable amount of misun-
derstanding. However, as clearly stated in the main part of
the article, an “uncertain” classification was “. . .not
intended to be a negative recommendation or preclude use
of that therapy. Rather it indicates a role for physician-
patient interaction in determining whether this treatment
may have merit in the context of its risk: benefit profile and
the individual characteristics, co-morbidities, and prefer-
ences of the patient” (3). In other words, OARSI privileges
the use of IAHA for specific clinical phenotypes, which
should be defined by the prescribing physician.
Finally, as recently highlighted by Altman et al (50), clini-
cal practice guidelines, and a fortiori recommendations for
the use of IAHA in the management of KOA, are not
intended to create uniformity and suppress treating physi-
cians’ self-analysis of the patient situation; they are designed
to provide the best evidence-based information available to
help physicians in making a treatment decision.
Mode of action
In the US, from a purely regulatory point of view, the symp-
tomatic effects of most of the IAHA preparations are consid-
ered to primarily result from the unique properties of HA in
solution; when injected intraarticularly, exogenous HA is
able to compensate for the drop in HA concentration and
chain length that has been observed during the progression
of OA, thus restoring the elastic and viscous properties of the
synovial fluid, which are responsible for its resistance to
compression and its lubricating effect, respectively (51,52).
However, these direct mechanical effects of exogenous HA
cannot account for its long-term benefits observed in clinical
trials (24), as it is cleared from the joint within a few days,
depending on the IAHA preparation. Over the past 30 years,
several possible pharmacologic mechanisms of action
explaining how the clinical effects of IAHA could persist for
several months have been proposed. A recent review of the
preclinical basic science literature performed by Altman
et al (53) highlighted the major role of HA binding to cluster
of differentiation 44 receptors in this complex mecha-
nism, as numerous of its mediated effects (e.g., inhibition of
Table 2. Recommendations for the use of intraarticular
hyaluronic acid in the management of knee
osteoarthritis*
Organization
(issue date) Recommendation
AAOS (2013) Recommends not using it (recommen-
dation 9 based on lack of evidence
for efficacy, and not on potential
harm) (15).
ACR (2012) Does not recommend it in the initial
management of the disease. Condi-
tionally recommends it in patients
with no satisfactory response to
prior recommended treatments (4).
ESCEO (2014) Recommends it in patients who are
severely symptomatic or still symp-
tomatic despite the use of NSAIDs,
or in case of contraindications to
NSAIDs (step 2) (14).
EULAR (2003) Recommends it for pain reduction and
functional improvement (2).
NICE (2014) Recommends not offering it (5).
OARSI (2014) Recommends it only after physician-
patient interaction for determining
whether it can have merit in the
context of their individual charac-
teristics, comorbidities, and prefer-
ences (based on an uncertain
appropriateness) (3).
* AAOS5American Academy of Orthopedic Surgeons; ACR5
American College of Rheumatology; NSAIDs5nonsteroidal anti-
inflammatory drugs; ESCEO5European Society for Clinical and
Economic Aspects of Osteoporosis and Osteoarthritis; EULAR5
European League Against Rheumatism; NICE5National Institute
for Health and Care Excellence; OARSI5Osteoarthritis Research
Society International.
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interleukin [IL]–1b, IL-6, and matrix metalloproteinase
[MMP] expression, and reduction in prostaglandin E2 syn-
thesis) contribute to the chondroprotection, proteoglycan/
glycosaminoglycan synthesis, antiinflammatory, and sub-
chondral effects as observed in vitro. Alternative pathways
involving HA binding to intercellular adhesion molecule 1
and modulation of transient receptor potential vanilloid
channel 1 activity (54) have also been described. In addition,
the toll-like receptor (TLR) signaling pathway has been sug-
gested to contribute to the antiinflammatory and anti-
catabolic (inhibition of inflammation-induced activation of
MMPs) effects of IAHA in joint tissues (55,56). Indeed, there
is evidence that HA fragments that are highly expressed in
the OA joint can transduce inflammatory signals through
TLR2, TLR4, or both. When exogenous HA is injected in the
joint, the proportion of these fragments is reduced, thus
modulating TLR-mediated innate immune responses.
The ESCEO group is not convinced that one mode of
action is sufficient to explain the therapeutic trajectory of
IAHA and privilege the hypothesis that several mechanisms
overlap and interact to relieve OA pain. Furthermore, in
vitro results obtained on chondrocytes may not be the same
as what happens clinically (i.e., in an anaerobic medium).
Systematically repeated treatment
Is it useful and acceptable to propose to re-inject patients
with a low level of pain? This very relevant issue in daily
clinical practice has been addressed in the AMELIA (Osteo-
arthritis Modifying Effects of Long-Term Intra-Articular
Adant) study (44), a long-term, randomized, placebo-
controlled trial carried out in 306 patients with symptomatic
KOA who received 4 consecutive cycles (5 weekly IA injec-
tions) of either noncrosslinked HA of biofermentative origin
or placebo. Followup visits were conducted at 6 months after
the first and second cycles and at 12 months after the third
and fourth cycles, resulting in a total study duration of 40
months. At the end of the study, the responder rate
according to the Outcome Measures in Rheumatology/
OARSI response criteria (57) was significantly higher in the
IAHA group than in the control group (80.5% versus 65.8%;
RR 1.22 [95% CI 1.07, 1.41], P50.004). More interestingly,
the number of responders to IAHA progressively increased
after each treatment cycle, while response to IA placebo
remained fairly stable, with a statistically significant
between-group difference from 1 year onward (P, 0.05). No
increase in AEs occurred with repeated cycles of IAHA.
Based on these results, the ESCEO task force encourages
the use of repeated cycles of IAHA in patients who
responded to the first injection, starting a new treatment
cycle as soon as the first symptoms appear.
Molecular weight
There are more than 80 marketed IAHA preparations world-
wide. They differ in many characteristics, including origin
Table 3. Pharmacoeconomic studies evaluating the cost-effectiveness of IAHA in the symptomatic treatment of knee
osteoarthritis*
Reference
Source of
data Country Duration
Product vs.
comparator Cost-effectiveness ICER
Waddell et al,
2001 (65)
Cohort† US 3 years Synvisc1AC vs. AC NA Dominant
Torrance et al,
2002 (66)
RCT (74) Canada 12 months Synvisc1AC vs. AC NA $10,000 Canadian
per QALY
Kahan et al,
2003 (67)
RCT (67) France 9 months Synvisc vs. CC e829 for 32%
improvement in
Lequesne index
Dominant
Yen et al,
2004 (68)
Cohort† Taiwan 6 months Artz vs. naproxen $1,538 US
per QALY
$42,000 US
per QALY
Mazie`res et al,
2007 (69)
Cohort (69) France 6 months Suplasyn vs. CC (BL) e528 for 27%
improvement in
Lequesne index
Dominant
Turajane et al,
2007 (70)
Retrospective
(75)
Thailand 2 years Hyalgan1AC vs. AC NA NA
Chou et al,
2009 (71)
Cohort (71) Taiwan 6 months Synvisc vs. CC (BL) $299,456 NT
per QALY‡
NA
Artz vs. CC (BL) $394,021 NT
per QALY
NA
Miller and Block
2014 (72)
Cohort (76) US 2 years Registered IAHA vs. CC† $12,800 US
per QALY
, $23,400 US
per QALY
Hatoum et al,
2014 (73)
RCTs (77,78) US 12 months Euflexxa vs. CC (BL) $21,281 US
per QALY
Dominant
Hatoum et al,
2014 (73)
RCTs (74,77,78) US 12 months Euflexxa vs. AC $8,816 US
per QALY
$38,741 US
per QALY
* ICER5 incremental cost-effectiveness ratio; AC5 appropriate care (e.g., nonpharmacologic therapy, nonsteroidal antiinflammatory drugs
[NSAIDs], analgesics, corticosteroids, total knee arthroplasty); NA5not available; RCT5 randomized controlled trial; QALY5 quality-adjusted life
year; CC5 conventional care (i.e., nonpharmacologic therapy, NSAIDs, analgesics); BL5 baseline.
† Hypothetical.
‡ $1 NT5 $0.0315 US (2008 exchange).
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(animal versus biofermentation), mean MW (500–6,000 kDa)
and MW distribution, molecular structure (linear,
crosslinked, and a mix of both), method of crosslinking, con-
centration (0.8–30 mg/ml), volume of injection (0.5–6.0 ml),
and posology. Some of the preparations include different
concentrations of additives, such as mannitol, sorbitol, or
chondroitin sulfate. While each of these parameters may the-
oretically have an impact on the effect of the IAHA treat-
ment, research has mostly focused on the potential
differences resulting from the size of HA. For this purpose,
the exogenous HA available for IA injections are divided
into 3 MW categories: low (500–730 kDa), intermediate
(800–2,000 kDa), and high (2,000–6,000 kDa), including
crosslinked formulations of HA (58). The rationale for an
influence of the MW results from research on the mode of
action of IAHA. Indeed, as summarized in the review by
Altman et al (53), basic preclinical science showed that
higher MW HAs may provide superior chondroprotective,
proteoglycan/glycosaminoglycan synthesis, antiinflammatory,
mechanical, and analgesic effects. Whether these differences
observed in vitro translate into clinical evidence is not clearly
established yet.
Two meta-analyses comparing different IAHA pre-
parations have been published to date (Table 1). The first one
compared hylan with lower-MW IAHA and found no clini-
cally relevant benefits in terms of efficacy of either type of
preparation. However, the risks for local AEs (RR 1.91 [95%
CI 1.04, 3.49]; I25 28%) and postinjection flares (RR 2.04
[95% CI 1.18, 3.53]; I25 0%) were observed to be twice as
high with hylan than with low- or intermediate-MW HA (22).
In addition, a higher number of pseudosepsis cases were
reported with hylan than with other IAHA preparations,
whose risk might increase with subsequent courses (40). In
the second meta-analysis, comparing different commercially
available IAHA products, the authors were not able to con-
clude that one brand had a better efficacy than another due to
the heterogeneity of the studies and outcomes (25).
In addition, most head-to-head RCTs performed to date
have found noninferiority with respect to symptomatic effi-
cacy between the various HA preparations evaluated
(59–64). To our knowledge, only 1 RCT was able to demon-
strate a statistically significant difference between 2 IAHA
preparations varying in MW regarding symptomatic efficacy.
Indeed, this study conducted in 400 patients with KOA
showed that an intermediate-MW HA provided statistically
superior pain relief at 6 months than a low-MW HA. Second-
ary end points confirmed the primary finding (58).
Based on the above, the ESCEO task force considers that
there is currently no clinical evidence supporting an advan-
tage in efficacy of one product over another. Furthermore, if
certain intrinsic properties (e.g., MW) of particular IAHA
preparations provide beneficial results in comparison with
other IAHA products, characteristics related to the patient
are likely to prevail.
Efficiency
Only 9 pharmacoeconomic studies evaluating the cost-
effectiveness of IAHA have been published to date (Table 3)
(65–73). Most of them were conducted in patients with KOA
who received IA injections of hylan (65–67,71).
Although pharmacoeconomic data are overall in favor of
IAHA, only a few evaluations included sensitivity analyses
or were performed based on RCTs. Furthermore, some costs
were not included, such as those associated with potential
AEs. Therefore, the ESCEO task force recommends investi-
gating more in the identification, measurement, and compar-
ison of the costs, risks, and benefits of IAHA in the
management of KOA.
Conclusion
This review addresses major aspects related to the use of
IAHA in the management of KOA. It emphasizes its good
safety profile and its moderate but real efficacy on symptoms,
which is in the same range as other pharmacologic treatment
modalities (e.g., NSAIDs) used in this indication. The effec-
tiveness of IAHA has also been highlighted based on real-life
clinical data and should therefore be helpful to clinicians
when making care decisions tailored to individual patient
needs.
The ESCEO working group is aware that IAHA is not a
panacea for treating a heterogeneous disease such as KOA.
However, KOA is known to mostly affect the elderly and
individuals with significant comorbidities, thereby con-
straining the use of several conventional therapeutic options
such as acetaminophen, NSAIDs, opioids, duloxetine, or TKA.
Therefore, the experts convened by the ESCEO feel that the
medical community cannot afford to neglect the use of
IAHA, particularly now that systematic repetitive treatment
cycles have been shown to yield positive results in terms of
both efficacy and safety. Indeed, they consider that IAHA is
a reasonable alternative in patients with KOA who have not
sufficiently responded to previous pharmacologic treatments,
and a key weapon in the therapeutic armamentarium for
managing KOA in patients with contraindications to conven-
tional interventions.
The ESCEO task force calls for additional well-conducted
clinical trials (RCTs, cohort studies) to define the predictive
factors (i.e., patient phenotypes, treatment characteristics)
associated with an optimal risk-benefit ratio. Such research
may further help in determining candidates that may take
most advantage of IAHA.
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